Last month it was widely reported that a new genetic test, costing just £50 could identify people at risk of a heart attack years or even decades in advance. Munich Re discusses the future impact on critical illness cover.
In actual fact the study referenced in many of the articles refers to a new Genomic Risk Score (GRS) developed by researchers based in Norway, with the early results of their study being published in the European Heart Journal. (Genomic prediction of coronary heart disease) The study, part-funded by the British Heart Foundation (BHF), looked at using DNA testing to assess a person's chance of developing coronary heart disease (CHD) much earlier in life and before symptoms even develop. Currently, heart disease risk is typically calculated through clinical and lifestyle indicators such...
To continue reading this article...
Join COVER for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, key trend analysis and industry insights.
- Stay on top of the latest developments around health and wellbeing, diversity and inclusion and the cost of living crisis.
- Receive breaking news stories straight to your inbox in the daily newsletter.
- Members only access to monthly programme 'The COVER Review'
- Be the first to hear about our CPD accredited events and awards programmes.
